drugset
Drugs / Miravirsen
last change Jan 2015 re-read 2 minutes ago

Miravirsen

also known as SPC3649 · Miravirsen sodium

Antisense oligonucleotide

Developed for
chronic hepatitis C virus infection · hepatitis C virus infection
Investigated by
Santaris Pharma A/S

Trials 5 · a red edge is where a trial was stopped

today NCT01872936 · Ph 2 NCT01727934 · Ph 2 NCT01646489 · Ph 1 NCT01200420 · Ph 2 NCT00688012 · Ph 1
20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01646489 Jun → Sep 2012 chronic hepatitis C virus infection Santaris Pharma A/S Completed No outcome recorded
Phase 1 NCT00688012 May 2008 → May 2009 hepatitis C virus infection Santaris Pharma A/S Completed No outcome recorded
Phase 23 trials
Phase 2 NCT01872936 Jun 2013 → Jan 2015 chronic hepatitis C virus infection Santaris Pharma A/S Unknown No outcome recorded
Phase 2 NCT01727934 Nov 2012 → Jan 2014 hepatitis C virus infection Santaris Pharma A/S Unknown No outcome recorded
Phase 2 NCT01200420 Sep 2010 → Dec 2011 chronic hepatitis C virus infection Santaris Pharma A/S Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00979927 Comparator Sep 2009 → Sep 2010 hepatitis C virus infection Santaris Pharma A/S Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Miravirsen ClinicalTrials.gov intervention name — accepted as the source's own label NCT01646489 ↗
3

NCT01727934 ↗

NCT01872936 ↗

NCT01200420 ↗
Known as Miravirsen sodium “Drug: Miravirsen sodium” NCT01727934 ↗
Known as SPC3649 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00688012 ↗
1

NCT00979927 ↗
Action Inhibit “Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting...” PMID 23534542 ↗ Mar 2013
Modality Antisense oligonucleotide “Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting...” PMID 23534542 ↗ Mar 2013
Route Subcutaneous “The patients were randomly assigned to receive five weekly subcutaneous injections of miravirsen at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or placebo over a...” PMID 23534542 ↗ Mar 2013